Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...

A licensing deal with Denmark’s Gubra gives the immunology giant control of an experimental therapy that could compete with ...

Takeda paid Protagonist $300 million one year ago to license rights to rusfertide, which the companies are developing to ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer ...

"Any place that gets cut, it's going to have an impact, because there's not any spare personnel at FDA,” said former agency ...

The meeting, which helps the FDA give guidance to vaccine makers on which flu strains to target, is the second to be ...

The brain drug developer is continuing a trial despite a recommendation it be stopped for futility. Elsewhere, Eli Lilly ...

While announcing billions of dollars in new U.S. investments, David Ricks called for an extension of 2017 tax cuts and ...

The funding comes as Eikon, run by former Merck research chief Roger Perlmutter, has started a Phase 3 trial testing one of ...

The Trump administration’s plans to reduce NIH grant funding could have long-term consequences for the U.S. drug industry, ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry ...

The deal comes amid an uptick in so-called SPAC deals, which had fallen out of favor due to poor returns and increased ...